
BIOA Stock Forecast & Price Target
BIOA Analyst Ratings
Bulls say
Bioage Labs is an attractive investment due to its focus on the biology of human aging and chronic inflammation, which are key areas of drug development. Their technology platform and human-aging data set adds a competitive advantage, and with a four-year cash runway and upcoming catalysts in 2026 and 2027 for their lead candidate, BGE-102, in cardiovascular and ocular disease, respectively, the company is poised for success. Additionally, the potential for their second drug, BGE-105, to have a strong synergy with weight loss drugs bodes well for their pipeline. While risks are inherent in the biotechnology industry, Bioage Labs' approach and potential make it a prime candidate for further growth.
Bears say
Bioage Labs is a clinical-stage biopharmaceutical company with high risks in the biotechnology sector due to potential regulatory, commercial, and partnership risks. Its lead program, BGE-102, is still in early development, with Phase 2 proof-of-concept data expected several years from now. The company also faces competitive pressure from better capitalized pharmaceutical giants in the same space, and its current valuation may not be fully justified by its limited product pipeline and potential for revenue generation in the near future.
This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares